Stockwatch: All that glisters is not predictable
This article was originally published in Scrip
Executive Summary
Dendreon’s restructuring announced on September 8, came after the disappointing second quarter sales of its bespoke prostate cancer vaccine Provenge (sipuelcel-T) which also resulted in the company’s sales guidance for the year being withdrawn (scripintelligence.com, 8 September 2011). It now appears that Dendreon’s woes might be a wake-up call, not just for investors who are also watching new product launches this year from other companies, but also the Securities and Exchange Commission (SEC) on disclosure policies and so-called black-out periods when company management is prevented from selling stock.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.